Xu D, Kang H, Fisher M, Juliano RL. Strategies for inhibition of MDR1 gene
expression. Mol Pharmacol 2004;66:268–275.
Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y. Uptake is the rate-limiting step in
the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res
1996;13:1559–1564.
Yamazaki M, Akiyama S, Ni’inuma K, Nishigaki R, Sugiyama Y. Biliary excretion of
pravastatin in rats: contribution of the excretion pathway mediated by canalicular
multispecific organic anion transporter (cMOAT). Drug Metab Dispos
1997;25:1123–1129.
Yin JAL, Wheatley K, Rees JKH, Burnett AK. Comparison of \‘‘sequential\’’ versus\
‘‘standard\’’ chemotherapy as re-induction treatment, with or without cyclosporine, in
refractory/relapsed acute myeloid leukemia (AML): results of the UK medical research
council AML-R trial. Br J Haemat 2001;113:713–726.
Yu D. The contribution of P-glycoprotein to pharmacokinetic drug–drug interactions.
J Clin Pharmacol 1999;39:1203–1211.
Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA. Breast cancer resistance
protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and
elimination in the mouse. Mol Pharm 2006;3:55–61.
Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E.
Effect of grapefruit juice on the pharmacokinetics of Losartan and its active
metabolite E3174 in healthy volunteers. Ther Drug Monit 2001;23:369–373.
Zamek-Gliszczynski MJ, Hoffmaster KA, Tian X, Zhao R, Polli JW, Humphreys JE,
Webster LO, Bridges AS, Kalvass JC, Brouwer KLR. Multiple mechanisms are
involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2
and BCRP1. Drug Metab Dispos 2005;33:1158–1165.
202 DRUG TRANSPORTERS IN DRUG DISPOSITION, DRUG INTERACTIONS